China Pharma Holdings, Inc. [[CPHI.OB]], which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval to list its securities on NYSE Amex.

China Pharma expects to begin trading on NYSE Amex on Wednesday, September 30, 2009. In connection with its listing on NYSE Amex, the Company’s ticker symbol will change to “CPHI” from “CPHI.OB.”

Ms. Zhilin Li, CEO and President of China Pharma, commented, “It is a major milestone to move to NYSE Amex, and we are proud of our fulfillment of this target. We believe that NYSE Amex provides excellent exposure for companies from emerging markets, such as ours. This step underscores our commitment to generating long-term value for our shareholders.”

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

GC China Turbine Corp. (GCHT) at a time of growing support for global environmental issues this week marks a milestone for the United Nations as well as for GC China Turbine Corp. Nearly 100 world leaders agreed to participate in an historic Summit on Climate Change in New York this week in order to mobilize political will and strengthen momentum for a fair, effective, and ambitious climate deal in Copenhagen this December.

The Summit marks the first UN visit for the Presidents of China and the United States. This participation clearly underlines the degree of commitment to change at the highest levels of world government. “Failure to reach broad agreement in Copenhagen would be morally inexcusable, economically short-sighted and politically unwise,” the Secretary-General said in his opening address. “Now is the moment to act in common cause.”

It is against this backdrop of political will and resultant extraordinary potential for increased industry momentum that will directly affect the future positive growth of the wind power sector in China, that GC China Turbine Corp. is pleased to announce the final framework for a definitive agreement (the “Agreement”) with Wuhan Guoce Nordic New Energy Co. Ltd., a People’s Republic of China Company (“GC Nordic”), and all related parties have met, thus paving the way for the execution of the share exchange agreement by the end of the month.

All parties have agreed to the terms and conditions of a formal, definitive agreement, which will see the Company consummate a voluntary share exchange with the parent company of GC Nordic by acquiring all of the issued and outstanding capital stock of the parent company of GC Nordic in exchange for the issuance of shares of common stock of the Company, which will represent a fifty four percent (54%) ownership interest in the Company post-Closing (the “Exchange”). As a result, upon consummation of the Exchange, the Company shall indirectly own all of the outstanding capital stock of GC Nordic. Furthermore, the previously announced $10,000,000 loan made to the Company will be converted into shares of the Company’s common stock.

It is anticipated that an announcement of the formal closing providing further details of the agreement will be made shortly.

Wuhan Guoce Nordic New Energy Co. Ltd. (GC Nordic) is a wind turbine manufacturing venture and affiliate of the highly regarded and successful multi-division Wuhan Guoce Group of Companies. The organization is a well established manufacturer of hydraulic and electronic systems offering direct access to a national client base representing a large industrial market share with extensive vertical penetration opportunities across the People’s Republic of China (“PRC”). The company holds a license to manufacture a robust and innovative wind turbine system originally developed in Europe.

Further details regarding the Company and complete details of the Exchange with GC Nordic are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

CDC Software Corporation (CDCS), a global provider of enterprise software applications and services, today announced, at a press conference in Shanghai, that it has executed a term sheet to acquire up to a 51 percent stake, in three tranches prior to March 31, 2012, in Beijing-based Hejia Software Technology Co. Ltd, a major ERP software provider in China.

The acquisition of this interest in Hejia Software is subject to several customary closing conditions, including the execution of definitive documentation related to the deal, the receipt of all requisite approvals and consents, and the satisfactory completion of due diligence by CDC Software.

Founded in 1998, Hejia Software Technology is a major ERP vendor in the China enterprise market, and currently has offices in Shanghai, Guangzhou, Changzhou, and other places throughout the China region. The company’s main product, HJSOFT, is a web-based solution featuring functionality in supply chain management, ERP, quality assurance, financial management, and customer relationship management. Hejia Software’s products are used by more than 400 customers in industries that include Industrial, Food and Beverage, Healthcare, Publishing and Chemical. Some of Hejia Software’s customers include Changlin Company Limited, Shandong Dong-e E-Jiao Group, Zizhu Pharmaceutical, Coca-Cola, Bosch Rexroth, Novo Nordisk, and Hörmann.

In the event the acquisition is completed, Hejia Software Technology will be the latest addition to CDC Software’s successful Franchise Partner Program and the second franchise partner in China following last year’s previously announced acquisition of a majority stake in Integrated Solutions Ltd. (ISL), a provider of ERP solutions for small and medium-sized discrete manufacturers. Formed in 2006, CDC Software’s Franchise Partner Program helps CDC Software establish strategic relationships with partners in selected geographies, with a focus on emerging markets, through majority control, as well as minority investments. CDC Software currently has seven other franchise partners located in India, China, South America, Spain and Mexico.

The acquisition of Hejia Software Technology is part of CDC Software’s strategic plans to expand its geographic footprint and increase sales by accessing rapidly growing economies. As part of that strategy, CDC Software expects to continue to pursue other strategic investments in China.

If the transaction is completed, Hejia Software is expected to resell CDC Software’s Ross ERP, CDC Supply Chain and CDC Platinum HRM through an OEM partnership in mainland China, and Hejia is also expected to leverage CDC Software’s extensive global infrastructure to expand sales of its own products.

“We are very pleased to invest in Hejia Software, a major ERP software provider in China that fits into our expansion strategy in that country,” said Peter Yip, CEO of CDC Software. “We believe China holds significant growth opportunity for the enterprise software market and that this investment will help us to increase our market penetration in this country. Hejia is also expected to help us accelerate our organic growth rate as Hejia will help sell CDC Software solutions into the China market. Together with other potential investments and partnerships, we hope to see sales in China making up a more significant portion of our revenue in the near future.”

“We are excited about CDC Software’s investment in Hejia Software,” Chen Jia, chairman and CEO of Hejia Software. “CDC Software’s Franchise Partner Program investments and acquisitions have performed well under support from CDC Software’s global infrastructure. Together, we hope to not only help build Hejia Software’s market share, but also further expand CDC Software’s products into this potentially lucrative market.”

This pending acquisition also represents a continuation of CDC Software’s restarted investment program following the completion of its initial public offering on August 6, 2009. Earlier this month, CDC Software completed its previously announced acquisition of Categoric, a supply chain event management software provider.

China Natural Gas, Inc. (CHNG), a leading provider of compressed natural gas (CNG) for vehicular fuel and pipeline natural gas for industrial, commercial and residential use in Xi’an, China, today announced that it closed the sale of an additional 858,750 shares of common stock at the public offering price of $8.75 per share, pursuant to the over-allotment option exercised in full by the underwriter in connection with its public offering that closed on September 9, 2009.

The exercise of the over-allotment option brings the total number of shares sold by China Natural Guess in this public offering to 6,583,750. The aggregate net proceeds received by the Company totaled approximately $54.7 million, after deducting underwriting discounts and commissions and the Company’s roadshow travel expenses but before other expenses.

Roth Capital Partners, LLC acted as the sole book runner for the offering, and Simmons & Company International acted as a co-manager for the offering.

The net proceeds from the offering will be used for the construction of the Company’s liquefied natural gas (LNG) facility, the acquisition of eight CNG fueling stations, the purchase of eight CNG trucks to transport CNG and the establishment of a joint venture company with China National Petroleum Corporation Kunlun Natural Gas Co., Ltd., as well as for general working capital purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement relating to this offering may be obtained from Roth Capital Partners, LLC, Attention: Equity Capital Markets, 24 Corporate Plaza Drive, Newport Beach, CA 92660, by telephone at (949) 720-7194, or via email at rothecm@roth.com .

About China Natural Gas, Inc.

China Natural Gas transports and sells natural gas to vehicular fueling terminals, as well as commercial, industrial and residential customers through its distribution networks in China’s Shaanxi and Henan Provinces. The Company owns approximately 120 km of high pressure pipelines and operates 23 CNG fuelling stations in Shaanxi Province and 12 CNG fuelling stations in Henan Province. China Natural Gas’ four primary business lines include: (1) the distribution and sale of CNG through Company-owned CNG fuelling stations for hybrid (natural gas/gasoline) powered vehicles; (2) the installation, distribution and sale of piped natural gas to residential, commercial and industrial customers through Company-owned pipelines; (3) the distribution and sale of gasoline through Company-owned CNG fuelling stations for hybrid (natural gas/gasoline) powered vehicles; and (4) the conversion of gasoline — fueled vehicles to hybrid (natural gas/gasoline) powered vehicles through its auto conversion division.